Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLET
NCT02322814Phase 2Terminated
- Sponsor
- Roche
- Start
- Mar 2015
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial of cobimetinib in triple-negative breast cancer (TNBC) (4 cohorts), sponsored by Roche. Primary endpoints: Progression-Free Survival up to 2 years and Overall Response Rate up to 5.25 years. Started Mar 2015; status: terminated.
02
Drugs
cobimetinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02322814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02322814.